Inositol treatment of Alzheimer's disease: a double blind, cross-over placebo controlled trial

Prog Neuropsychopharmacol Biol Psychiatry. 1996 May;20(4):729-35. doi: 10.1016/0278-5846(96)00043-7.

Abstract

1. A double-blind controlled crossover trial of 6 gm of inositol daily vs glucose for one month each was carried out in 11 Alzheimer patients. 2. Overall CAMCOG scores showed a trend for greater improvement with inositol that was not significant. 3. Language and orientation improved significantly more on inositol than on placebo. There were no serious side effects. 4. Higher doses of inositol should be studied in Alzheimer's Disease for longer periods.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial

MeSH terms

  • Aged
  • Aged, 80 and over
  • Alzheimer Disease / drug therapy*
  • Alzheimer Disease / psychology
  • Cross-Over Studies
  • Double-Blind Method
  • Female
  • Humans
  • Inositol / therapeutic use*
  • Language
  • Orientation / physiology
  • Psychiatric Status Rating Scales

Substances

  • Inositol